MTOR (Redirect)

MTOR

Pathway Diagram

Overview

mTOR (mechanistic target of rapamycin) is a serine/threonine protein kinase that functions as a master regulator of cellular growth, metabolism, and autophagy. As a central hub in nutrient-sensing pathways, mTOR integrates signals from amino acids, glucose, growth factors, and energy status to coordinate anabolic and catabolic processes. The mTOR protein exists in two functionally distinct complexes: mTORC1 (mTOR complex 1), which primarily promotes protein synthesis and inhibits autophagy, and mTORC2 (mTOR complex 2), which regulates cytoskeletal organization and cell survival. Dysregulation of mTOR signaling has emerged as a critical factor in multiple neurodegenerative diseases, making it a major focus of translational neurodegeneration research.

Function/Biology

MTOR

Pathway Diagram

Overview

mTOR (mechanistic target of rapamycin) is a serine/threonine protein kinase that functions as a master regulator of cellular growth, metabolism, and autophagy. As a central hub in nutrient-sensing pathways, mTOR integrates signals from amino acids, glucose, growth factors, and energy status to coordinate anabolic and catabolic processes. The mTOR protein exists in two functionally distinct complexes: mTORC1 (mTOR complex 1), which primarily promotes protein synthesis and inhibits autophagy, and mTORC2 (mTOR complex 2), which regulates cytoskeletal organization and cell survival. Dysregulation of mTOR signaling has emerged as a critical factor in multiple neurodegenerative diseases, making it a major focus of translational neurodegeneration research.

Function/Biology

mTOR operates as part of two multi-protein complexes with distinct compositions and substrate specificities. mTORC1 contains mTOR, Raptor (regulatory-associated protein of mTOR), mLST8/GβL, PRAS40, and DEPDC5, among other components. This complex phosphorylates substrates including S6K (ribosomal S6 kinase) and 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1) to promote protein synthesis and ribosome biogenesis. mTORC1 also phosphorylates ULK1 (unc-51-like kinase 1), which suppresses autophagy initiation.

mTORC2, containing mTOR, Rictor (rapamycin-insensitive companion of mTOR), mLST8, SIN1, and PROTOR proteins, phosphorylates AKT (also called PKB), SGK1, and PKC isoforms to regulate cell survival and metabolism. The two complexes are regulated by distinct inputs: mTORC1 responds to amino acids through the Rag GTPases and GATOR complexes, while both complexes respond to growth factors through the PI3K/AKT and MAPK/ERK pathways. Energy status, sensed through AMP-activated protein kinase (AMPK), inhibits mTORC1 through phosphorylation of tuberous sclerosis complex proteins TSC1/TSC2.

Role in Neurodegeneration

Compelling evidence implicates mTOR dysregulation in major neurodegenerative diseases. In Alzheimer's disease, excessive mTORC1 signaling correlates with reduced autophagy and accumulation of amyloid-beta and phosphorylated tau pathology. Conversely, mTORC1 inhibition enhances clearance of these pathogenic proteins. Similar patterns emerge in Parkinson's disease, where alpha-synuclein accumulation is suppressed by mTOR inhibition, and in ALS, where mTOR dysregulation impacts motor neuron survival and TDP-43 pathology. In Huntington's disease, mutant huntingtin protein disrupts mTOR signaling, impeding autophagy and exacerbating neuronal toxicity.

The key mechanistic link involves autophagy: mTORC1 inhibition relieves suppression of ULK1, permitting autophagosome formation and clearance of neurotoxic protein aggregates. Additionally, mTOR regulates mitochondrial function, synaptic plasticity, and neuroinflammation—all relevant to neurodegeneration. Excessive mTORC1 activity also promotes mTORC1-mediated phosphorylation of S6K, which can inhibit insulin receptor substrate (IRS) signaling, creating a negative feedback that paradoxically reduces growth factor signaling.

Molecular Mechanisms

The molecular basis of mTOR dysfunction in neurodegeneration involves several pathways. In Alzheimer's disease, amyloid-beta and tau pathology directly impair TSC1/TSC2 complex function, leading to constitutive mTORC1 activation. This hyperactivation suppresses ULK1-mediated autophagy and impairs trafficking of autophagosomes to lysosomes. In Parkinson's disease and ALS, mutations affecting upstream regulators like PINK1 (in mitochondrial quality control) or SOD1 disrupt mTOR signaling balance.

mTOR also regulates translation of specific mRNAs through 4E-BP1 phosphorylation, including those encoding proteins involved in synaptic function and neuronal survival. Aberrant mTOR-mediated translation contributes to excitotoxicity and synaptic dysfunction in neurodegeneration. Furthermore, mTORC2-mediated AKT phosphorylation regulates glycogen synthase kinase 3-beta (GSK3β), which phosphorylates tau protein; thus mTOR signaling dysregulation indirectly impacts tau pathology.

Clinical/Research Significance

mTOR inhibitors, particularly rapamycin and rapalogs (analogs of rapamycin), have demonstrated neuroprotective effects in preclinical models of multiple neurodegenerative

See Also

• [AMPK Agonist Therapy for Neurodegeneration](/wiki/ideas-payload-ampk-agonist-neurodegeneration) — activates
• [AMPK Agonist Therapy for Neurodegeneration](/wiki/ideas-payload-ampk-agonist-neurodegeneration) — associated_with